← ANALYST RATINGS · TIPRANKS
Repligen (RGEN): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy1 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $197, the highest $225, the lowest $145. The average is +12.1% from the last price of $175.
Analyst ratings 20
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $175 → $200+14.3% | Buy | +14.0% | Reiterated | 16.10.26on TipRanks Oct 17 08:15 | −3.6% | ↗ |
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $184 → $203+10.3% | Buy | +15.7% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $176 → $193+9.7% | Hold | +10.0% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $180 → $198+10.0% | Hold | +12.9% | Downgrade | 16.10.26on TipRanks 08:05 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $172 → $190+10.5% | Hold | +8.3% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $186 → $205+10.2% | Buy | +16.9% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $179 → $198+10.6% | Hold | +12.9% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $209 → $184−12.0% | Buy | +4.9% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $196 → $176−10.2% | Hold | +0.3% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $209 → $180−13.9% | Hold | +2.6% | Downgrade | 08.10.26on TipRanks 15:05 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $197 → $172−12.7% | Hold | −1.9% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $213 → $186−12.7% | Buy | +6.0% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $207 → $179−13.5% | Hold | +2.0% | Reiterated | 08.10.26on TipRanks 15:05 | — | |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $175 → $225+28.6% | Buy | +28.3% | Reiterated | 07.10.26on TipRanks 03:55 | −4.1%next day −1.6% · 5 days +7.5% | ↗ |
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $196 → $209+6.6% | Buy | +19.1% | Upgrade | 06.10.26on TipRanks 10:05 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $190 → $196+3.2% | Hold | +11.7% | Reiterated | 06.10.26on TipRanks 10:05 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $196 → $209+6.6% | Buy | +19.1% | Upgrade | 06.10.26on TipRanks 10:05 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $186 → $197+5.9% | Hold | +12.3% | Reiterated | 06.10.26on TipRanks 10:05 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $203 → $213+4.9% | Buy | +21.4% | Reiterated | 06.10.26on TipRanks 10:05 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $194 → $207+6.7% | Hold | +18.0% | Reiterated | 06.10.26on TipRanks 10:05 | — | |
| Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% | Wolfe Research | $225 | Buy | +28.3% | Reiterated | 29.09.26on TipRanks 06:25 | +0.4%next day −1.0% · 5 days −12.1% | ↗ |
| Matt Hewitt★★★★★★★★★★#3011 · hits 47% · avg +4.1% | Craig-Hallum | — | Buy | — | Reiterated | 25.09.26on TipRanks Sep 28 02:05 | −1.1%next day +3.1% · 5 days −4.0% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | — | Buy | — | Reiterated | 15.09.26on TipRanks Sep 16 05:10 | +4.5%next day −0.6% · 5 days +4.5% | ↗ |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $165 → $175+6.1% | Buy | −0.2% | Assigned | 29.07.26on TipRanks 08:18 | −1.3%next day 0.0% · 5 days +6.8% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $145 | Hold | −17.3% | Reiterated | 28.07.26on TipRanks Jul 29 11:15 | +10.7%next day −1.3% · 5 days −1.1% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $160 → $185+15.6% | Buy | +5.5% | Reiterated | 28.07.26on TipRanks Jul 29 06:57 | +10.7%next day −1.3% · 5 days −1.1% | ↗ |
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | $200 | Buy | +14.0% | Reiterated | 28.07.26on TipRanks Jul 29 01:50 | +10.7%next day −1.3% · 5 days −1.1% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 28.07.26on TipRanks 10:16 | +10.7%next day −1.3% · 5 days −1.1% | ↗ |
| Robert Wasserman★★★★★★★★★★#2200 · hits 44% · avg +9.2% | Benchmark Co. | $185 | Buy | +5.5% | Upgrade | 07.07.26on TipRanks 06:41 | −0.7%next day −1.4% · 5 days +4.7% | ↗ |
| Daniel Markowitz CFA★★★★★★★★★★#1752 · hits 61% · avg +22.3% | Evercore ISI | $150 → $160+6.7% | Buy | −8.8% | Reiterated | 06.07.26on TipRanks 08:55 | −1.5%next day −0.7% · 5 days +2.7% | ↗ |
| Yessica Sanchez Gudino★★★★★★★★★★#8150 · hits 100% · avg +14.0% | HSBC | $170 → $150−11.8% | Buy | −14.5% | Reiterated | 03.06.26on TipRanks 12:35 | +1.2%next day +3.6% · 5 days +11.2% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | $145 | Buy | −17.3% | Initiated | 01.06.26on TipRanks 16:40 | −1.7%next day +1.2% · 5 days +10.4% | ↗ |
| Unknown Analyst | Guggenheim | — | Hold | — | Reiterated | 07.05.26on TipRanks May 9 10:06 | +0.8%next day −3.2% · 5 days −20.5% | ↗ |
| Matthew Stanton, CFA★★★★★★★★★★#10524 · hits 43% · avg −10.9% | Jefferies | $152 → $142−6.6% | Hold | −19.1% | Reiterated | 05.05.26on TipRanks 15:50 | +5.5%next day −1.3% · 5 days −11.6% | ↗ |
| Natalya Davies★★★★★★★★★★#4625 · hits 89% · avg +16.4% | Rothschild & Co Redburn | $160 | Buy | −8.8% | Initiated | 17.04.26on TipRanks 04:55 | +2.0%next day +0.8% · 5 days −10.9% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $208 | Buy | +18.6% | Reiterated | 23.03.26on TipRanks 06:15 | +1.1%next day +0.3% · 5 days −0.6% | ↗ |
| Brandon Couillard★★★★★★★★★★#287 · hits 63% · avg +18.4% | Wells Fargo | $190 → $180−5.3% | Buy | +2.6% | Reiterated | 25.02.26on TipRanks 06:55 | −2.7%next day +1.7% · 5 days −3.6% | ↗ |
| Paul Knight★★★★★★★★★★#4215 · hits 45% · avg +3.5% | KeyBanc | $220 | Buy | +25.4% | Reiterated | 25.02.26on TipRanks 04:55 | −2.7%next day +1.7% · 5 days −3.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Repligen
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 07.10.26: target $192 at a price of $175 (+10.1%); now: $197 at $175 (+12.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 0 | 0 | 0 |
| Buy | 9 | 13 | 21 | 18 | 17 | 7 |
| Hold | 4 | 4 | 5 | 2 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 27.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.46 (from $0.41 to $0.50). Last quarter: $0.54.
Sales
Next quarter’s sales estimate — $207M (from $205M to $208M). Last quarter: $204M.
Best top-analyst consensus in the sector · Healthcare
About Repligen
- CEO: Olivier Loeillot
- Employees: 2,000
- Building 1, Waltham, MA, 02453, US
- www.repligen.com
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on th
Data from the stock’s TipRanks forecast page, read 8 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗